Fresenius Medical Care with clear analyst picture, shares in the DAX healthcare focus
23.06.2026 - 13:18:22 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:15.
Fresenius Medical Care (DE0005785802) starts the new trading week with a stable analyst consensus and a focus on its role in the DAX health-care segment on Xetra, while peers like Fresenius SE and other European medtech names set reference points for investors. Analyst data from several platforms show a broadly constructive stance on the stock despite a challenging reimbursement environment.
What analysts are signaling now
MarketScreener’s latest consensus overview for Fresenius Medical Care points to a mix of Buy and Hold recommendations, with only a minority of analysts on the Sell side and an average target price that implies moderate upside from current levels, according to the platform’s compiled data as of mid-June 2026.MarketScreener consensus data The consensus market capitalization figure for the company is around the high single-digit billion-euro range, underlining its weight within European health-care indices.Finanzen.net analyst overview
Analysts regularly cite the company’s global dialysis footprint and cost-efficiency initiatives as core elements of their investment cases, while also flagging reimbursement risks in the United States and Europe as the main valuation constraints. In recent notes, research houses stress the importance of margin stability and cash generation, particularly after the sector’s experience with inflationary pressure on personnel and clinical supplies in 2024 and 2025.
Tuesday focus on consensus and peers
On Tuesday the spotlight for Fresenius Medical Care lies on how its shares are priced relative to European health-care peers including its former parent Fresenius SE, with valuation metrics such as the price-earnings ratio and the dividend yield forming important reference points for institutional investors who benchmark against the DAX and Stoxx Europe 600 health-care sub-indexes.Börse Frankfurt company profile On finanzen.net, recent data show Fresenius Medical Care trading at a mid-teens earnings multiple, which places it in line with or slightly below some specialist medtech peers when adjusted for growth and balance-sheet structure.Finanzen100 share overview
Research commentary also compares the stock’s risk-reward profile to that of other dialysis and hospital operators, with some analysts arguing that Fresenius Medical Care’s global scale and integrated care offerings justify a premium over smaller regional players. Others emphasize that the company’s exposure to public payers and fixed reimbursement schedules calls for a valuation discount relative to high-growth medical-technology firms with more pricing flexibility.
All news and analysis on the Fresenius Medical Care shares
Further company reports, estimates and price data provide a broader picture for investors following Fresenius Medical Care over the medium term.
How Fresenius Medical Care earns its money
Fresenius Medical Care generates the bulk of its revenue with chronic kidney failure patients through a network of dialysis clinics and the sale of dialysis products such as hemodialysis machines and dialyzers, complemented by related services including laboratory diagnostics and care coordination. The business model combines recurring treatment income with equipment and consumable sales to internal clinics and external customers.
Where the shares trade today
The Fresenius Medical Care shares (DE0005785802) most recently traded on Xetra at around the mid-30-euro range per share on 2026-06-23, 11:00, according to exchange data, with the exact quote fluctuating during the session in line with broader DAX health-care moves.
Key data on the Fresenius Medical Care shares
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra
- Price (as of 2026-06-23, 11:00): mid-30s EUR range (exact level intraday)
- Market cap: high single-digit billion EUR range (as of 2026-06-23)
- Sector / industry: Health Care - Health Care Providers & Services / Medical Equipment
- Index membership: DAX / DAX health-care segment
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. All information has been compiled with care, but without any claim to completeness or accuracy. Figures and assessments may change at any time without notice.
